H
Howard L. McLeod
Researcher at Central South University
Publications - 582
Citations - 37847
Howard L. McLeod is an academic researcher from Central South University. The author has contributed to research in topics: Pharmacogenetics & Cancer. The author has an hindex of 94, co-authored 568 publications receiving 34969 citations. Previous affiliations of Howard L. McLeod include Chinese Ministry of Education & University of Aberdeen.
Papers
More filters
Journal ArticleDOI
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
TL;DR: The existence of large population differences with small intrapatient variability is consistent with inheritance as a determinant of drug response; it is estimated that genetics can account for 20 to 95 percent of variability in drug disposition and effects.
Journal ArticleDOI
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Mark J. Rieder,Alexander P. Reiner,Brian F. Gage,Deborah A. Nickerson,Charles S. Eby,Howard L. McLeod,David K. Blough,Kenneth E. Thummel,David L. Veenstra,Allan E. Rettie +9 more
TL;DR: VKORC1 haplotypes can be used to stratify patients into low-, intermediate-, and high-dose warfarin groups and may explain differences in dose requirements among patients of different ancestries.
Journal ArticleDOI
Doxorubicin pathways: pharmacodynamics and adverse effects
Caroline F. Thorn,Connie Oshiro,Sharon Marsh,Tina Hernandez-Boussard,Howard L. McLeod,Teri E. Klein,Russ B. Altman +6 more
TL;DR: A brief background on the literature supporting the PharmGKB pathway about doxorubicin action, and a summary of this active area of research can be found in this paper.
Journal ArticleDOI
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
Brian F. Gage,Charles S. Eby,Julie A. Johnson,Elena Deych,Mark J. Rieder,Paul M. Ridker,Paul E. Milligan,Gloria R. Grice,Petra A. Lenzini,Allan E. Rettie,Christina L. Aquilante,Christina L. Aquilante,Leonard E. Grosso,Sharon Marsh,Taimour Y. Langaee,LE Farnett,Deepak Voora,Deepak Voora,David L. Veenstra,Robert J. Glynn,A Barrett,Howard L. McLeod,Howard L. McLeod +22 more
TL;DR: The goal was to develop and validate a pharmacogenetic algorithm that explained 53–54% of the variability in the warfarin dose in the derivation and validation cohorts.
Journal ArticleDOI
Genomics and Drug Response
TL;DR: This article reviews recent pharmacogenetic and pharmacogenomic advances and discusses how such advances are reflected in the labeling of drugs.